1 results match your criteria: "University of Texas M. D. Anderson Cancer Center-Investigational Cancer Therapeutics[Affiliation]"
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
Cancer Chemother Pharmacol
April 2017
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center-Investigational Cancer Therapeutics, 1515 Holcombe Blvd. Unit 455, Huston, TX, 77030, USA.
Purpose: A phase I two-period two sequence cross-over study compared the bioavailability of two pimasertib (MSC1936369B/AS703026) formulations (capsule versus tablet) in advanced cancer patients.
Methods: Patients with advanced solid tumors were randomized to one of two treatment sequences utilizing pimasertib tablet (test; 3 × 20 mg, PO QD) and capsule (standard; 2 × 30 mg, PO QD). The trial comprised a screening and baseline period, two time periods or parts A and B, and a trial extension phase.